Table 2.
Overview of outcomes reported in the studies
Study | Incident oral infection | Persisting oral infection | Incident anogenital infection | Persisting anogenital infection | Condyloma acuminatum | AIN grade 2 | AIN grade 3 or carcinoma | PIN grade 2 | PIN grade 3 or carcinoma | Severe adverse events | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anogenital | Anal | Anogenital | Anal | Genital | Anal | ||||||||
Randomized trials | |||||||||||||
Giuliano et al. 2011 [32] | x | x | x | xa | xa | x | |||||||
Palefsky et al. 2011 [33] | x | x | x | x | x | xb | |||||||
Coskuner et al. 2014 [31] | x | ||||||||||||
NCT01461096 [26] | x | ||||||||||||
Non-randomized studies | |||||||||||||
Swedish et al. 2012 [25] | xc | xc | |||||||||||
Swedish and Goldstone 2014 [34] | x | ||||||||||||
Kahn et al. 2015 [24] | x |
aPIN 2 and PIN 3 analysed together
bSubgroup of Giuliano et al. [32]; therefore, all severe adverse events already reported there
cdefined as “high-grade anal intraepithelial neoplasia”, comprising AIN 2 and AIN 3 (Goldstone, personal communication). Applying a conservative approach, results are reported here as AIN 2